[1] Ma YJ, Deng XL, Li HQ,et al. BRAF V600E mutation and its association with clinicopathological features of papillary thyroid microcarcinoma: a meta-analysis[J].J Huazhong Univ Sci Technolog Med Sci,2015, 35(4):591-599.
[2] Xu JM, Xu HX, Li XL, et al. A Risk model for predicting central lymph node metastasis of papillary thyroid microcarcinoma including conventional ultrasound and acoustic radiation force impulse elastography[J].Medicine (Baltimore),2016, 95(3):e2558.
[3] Cai YF, Wang QX, Ni CJ, et al. A scoring system is an effective tool for predicting central lymph node metastasis in papillary thyroid microcarcinoma: a case-control study[J].World J Surg Oncol,2016, 14(1):45.
[4] Wada N, Duh QY, Sugino K, et al. Lymph node metastasis from 259 papillary thyroid microcarcinomas: frequency, pattern of occurrence and recurrence, and optimal strategy for neck dissection[J].Ann Surg,2003, 237(3):399-407.
[5] Roh JL, Kim JM, Park CI. Central cervical nodal metastasis from papillary thyroid microcarcinoma: pattern and factors predictive of nodal metastasis[J].Ann Surg Oncol,2008, 15(9):2482-2486.
[6] 孙宇,石铁锋,于江涛,等. BRAFV600E 基因突变与甲状腺乳头状微小癌预后影响因素的相关性[J].中国普外基础与临床杂志, 2014,21(10):1226-1231.
[7] 唐小乔,张寅,桑剑锋.甲状腺微小乳头状癌中央区淋巴结转移的临床特点及清扫价值[J].局解手术学杂志,2016, 25(1):38-41.
[8] 王天琪.甲状腺癌35例临床分析[J].医学临床研究,2006, 23(3):358-359.
[9] Kim JY, Jung EJ, Park T, et al. Impact of tumor size on subclinical central lymph node metastasis in papillary thyroid microcarcinoma depends on age[J].World J Surg Oncol,2015, 13:88.
[10] Varshney R, Pakdaman MN, Sands N, et al. Lymph node metastasis in thyroid papillary microcarcinoma: a study of 170 patients[J].J Laryngol Otol,2014, 128(10):922-925.
[11] Ito Y, Miyauchi A.A therapeutic strategy for incidentally detected papillary microcarcinoma of the thyroid[J].Nat Clin Pract Endocrinol Metab,2007, 3(3):240-248.
[12] Cho SY, Lee TH, Ku YH, et al. Central lymph node metastasis in papillary thyroid microcarcinoma can be stratified according to the number, the size of metastatic foci, and the presence of desmoplasia[J].Surgery,2015, 157(1):111-118.
[13] 夏晓峰,董小牛,何庄建.甲状腺微小乳头状癌中央区淋巴结转移相关因素分析[J].浙江中西医结合杂志, 2014,24(12):1107-1110.
[14] Lee J, Song Y, Soh EY. Central lymph node metastasis is an important prognostic factor in patients with papillary thyroid microcarcinoma[J].J Korean Med Sci,2014,29(1):48-52.
[15] Conzo G, Pasquali D, Bellastella G, et al. Total thyroidectomy, without prophylactic central lymph node dissection, in the treatment of differentiated thyroid cancer. Clinical retrospective study on 221 cases[J].Endocrine,2013, 44(2):419-425.
[16] Roti E, Rossi R, Trasforini G, et al. Clinical and histological characteristics of papillary thyroid microcarcinoma: results of a retrospective study in 243 patients[J].J Clin Endocrinol Metab,2006, 91(6):2171-2178.
[17] Hay ID, Grant CS, Bergstralh EJ, et al. Unilateral total lobectomy: is it sufficient surgical treatment for patients with AMES low-risk papillary thyroid carcinoma[J]?Surgery,1998, 124(6):958-964.
[18] Takami H, Ito Y, Okamoto T, et al. Therapeutic strategy for differentiated thyroid carcinoma in Japan based on a newly established guideline managed by Japanese Society of Thyroid Surgeons and Japanese Association of Endocrine Surgeons[J].World J Surg,2011, 35(1): 111-121.
[19] Ma B, Wang Y, Yang S, et al. Predictive factors for central lymph node metastasis in patients with cN0 papillary thyroid carcinoma: A systematic review and meta-analysis[J].Int J Surg,2016, 28:153-161. |
2017, Vol. 34 
